AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Precision Medicine for Psoriatic Diseases and PsA Highlights Update

Description

The presentation focused on precision medicine for psoriatic diseases and provided updates on psoriatic arthritis (PsA) highlights. Precision medicine is likened to a tailored suit, aiming to individualize treatments based on genetics, biomarkers, and disease phenotypes, moving away from trial-and-error approaches. The current state reveals a growing understanding of disease endotypes and the development of biomarker-based assays to inform treatment decisions. Tools like the neutrophil lymphocyte ratio (NLR) have utility in guiding cardiovascular risk assessment and treatment choices. Digital health technology also shows promise in personalizing care through apps that track disease activity. Updates on clinical trials were shared, including head-to-head studies comparing different biologics and discussions on new treatments like bimikizumab, which targets IL-17A and IL-23. Additional studies are ongoing to explore preventing PsA in at-risk cohorts and assessing combination therapies. The aim is to enhance patient outcomes through tailored treatment approaches and ongoing research.

View more

Conclusions

  • Precision medicine in psoriatic disease aims to customize treatment based on individual factors such as genetics and disease phenotype, moving away from trial and error approaches.
  • Current precision medicine strategies include predicting comorbidity risks and matching treatments to specific phenotypes in psoriatic disease.
  • There are high-quality genetic and biomarker markers that predict drug responses, but many face limitations in clinical accessibility.
  • Enhanced understanding of endotypes in psoriatic disease could advance the field of precision medicine significantly.
  • Models like Mind.Px show potential for biomarker-based drug selection, but true unmet needs exist in treating psoriatic arthritis more effectively.
  • Recent studies document the efficacy of new biologic treatments, including bimekizumab, in achieving significant clinical responses and skin clearance in psoriatic arthritis.
  • The emerging role of digital health technologies and AI could facilitate more personalized patient monitoring and treatment optimization.
  • Group studies focusing on combinations of therapies present promising results for patients with complex disease conditions.
  • There is an ongoing effort to prevent the transition from psoriasis to psoriatic arthritis through targeted trials, emphasizing early intervention.
  • Overall, there is a call for a more rigorous and comprehensive approach to managing psoriatic diseases through precision medicine and targeted therapies.
  • Mease PJ, et al. Ann Rheum Dis. 2020;79:123-131.
  • Smollen JS, et al. Ann Rheum Dis. 2020;79:1310-1319.
  • Mclnnes IB, et al. Lancet. 2020;395(10235):1496-1505.
  • Elman SA, Perez-Chada LM, Armstrong A, Gottlieb AB, Merola JF. Psoriatic Arthritis: A Comprehensive Review for the Dermatologist. Part II: Screening and Management. J Am Acad Dermatol. 2024 Jun 8:S0190-9622(24)00852-1. PMID: 38857766.
  • Scher JU, Ogdie A, Merola JF, Ritchlin C. Nat Rev Rheumatol. 2019;15(3):153-166.
  • Gladman et al. Trials (2022) 23:743. https://doi.org/10.1186/s13063-022-06589-y.
  • MoonLake Press Release. March 10, 2024. ARGO trial 24 week data [Accessed March 10, 2024]
  • Mease PJ Rheum Ther 2024.